PureTech Health (LON:PRTC) Stock Price Crosses Below Two Hundred Day Moving Average – Time to Sell?

Shares of PureTech Health plc (LON:PRTC) crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of GBX 126.05 and traded as low as GBX 114. PureTech Health shares last traded at GBX 117.40, with a volume of 3,148,794 shares traded.

Analysts Set New Price Targets

Separately, Peel Hunt reiterated a “buy” rating and set a GBX 508 target price on shares of PureTech Health in a research report on Monday, July 13th. One research analyst has rated the stock with a Buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of GBX 508.

PureTech Health Stock Performance

The company has a market capitalization of £285.77 million, a price-to-earnings ratio of -2.55 and a beta of 0.77. The company has a 50 day moving average price of GBX 125.17 and a 200 day moving average price of GBX 126.05. The company has a debt-to-equity ratio of 6.33, a quick ratio of 2.51 and a current ratio of 6.59.

Insiders Place Their Bets

In other news, insider Michele Holcomb bought 93,944 shares of the stock in a transaction dated Wednesday, July 29th. The shares were bought at an average cost of GBX 1 per share, with a total value of £939.44. Also, insider Sharon Barber-Lui bought 93,944 shares of the business’s stock in a transaction that occurred on Wednesday, July 29th. The stock was purchased at an average price of GBX 1 per share, for a total transaction of £939.44. In the last quarter, insiders have purchased 617,569 shares of company stock valued at $18,063,751. 13.41% of the stock is currently owned by corporate insiders.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.